HomeQuestion

Is there a biomarker for which patients benefit from tarlatamab?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

Will you offer lurbinectedin with atezolizumab for patients with ES-SCLC during maintenance if they had brain metastases at baseline?

1 Answers

Would you consider bevacizumab for a patient with SCLC who has asymptomatic brain metastasis progression after CNS radiation while on maintenance immunotherapy?

1 Answers

How do you talk with your patients regarding radiographic expectations on surveillance CT after lung SBRT?

164 Answers

How would you manage a patient with metastatic NSCLC and high-level MET amplification who achieved a near CR on tepotinib but is unable to tolerate dose-reduced tepotinib?

21 Answers

Do you offer consolidation durvalumab in a patient who had pneumonitis requiring steroids following chemoradiation for LS-SCLC?

42 Answers

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service